Patents-Review.com
ClassID:

20161 ⎘

A61K9/5084 - CPC Classification

Classification description:

Medicinal preparations characterised by special physical form; Preparations in capsules, e.g. of gelatin, of chocolate; Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to or , e.g. for obtaining a specific release pattern or for combining different drugs

Recent Application in this class:
#1
20260097010
2026-04-09

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #2
20260091013
2026-04-02

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #3
20260083696
2026-03-26

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #4
20260076913
2026-03-19

STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF

 #5
20260069545
2026-03-12

MODIFIED RELEASE FORMULATIONS OF IBUDILAST

 #6
20260027063
2026-01-29

Compositions for Treatment of Attention Deficit Hyperactivity Disorder

 #7
20260014111
2026-01-15

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #8
20250325538
2025-10-23

Methods of Using Low Dose Naltrexone to Treat Chronic Pain

 #9
20250295598
2025-09-25

MULTICOMPONENT CAPSULES

 #10
20250281416
2025-09-11

COATED NANOPARTICLE AGGREGATES COMPOSED OF A HYDROLYZED METAL SALT AND METHODS OF USE THEREOF

 #11
20250221946
2025-07-10

PHARMACEUTICAL COMPOSITION CONTAINING VITAMIN K2 FOR IMPROVING CARDIOVASCULAR CALCIFICATION, PREPARATION METHOD THEREFOR AND USE THEREOF

 #12
20250205187
2025-06-26

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #13
20250177332
2025-06-05

PHARMACEUTICAL DOSAGE FORM OF LACOSAMIDE

 #14
20250161225
2025-05-22

FUMARIC ACID COMPOSITIONS WITH INCREASED BIOAVAILABILITY AND REDUCED SIDE EFFECTS

 #15
20250152546
2025-05-15

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #16
20250099417
2025-03-27

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #17
20250090525
2025-03-20

Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate

 #18
20250025437
2025-01-23

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #19
20250025433
2025-01-23

LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF

 #20
20250009705
2025-01-09

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #21
20250009704
2025-01-09

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #22
20250000788
2025-01-02

BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS

 #23
20240423922
2024-12-26

TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION

 #24
20240374549
2024-11-14

Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics

 #25
20240374528
2024-11-14

MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE

 #26
20240366591
2024-11-07

Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2

 #27
20240366548
2024-11-07

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #28
20240366547
2024-11-07

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #29
20240358667
2024-10-31

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #30
20240358666
2024-10-31

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #31
20240350420
2024-10-24

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERHIDROSIS

 #32
20240325313
2024-10-03

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI

 #33
20240299346
2024-09-12

DIETARY SUPPLEMENT BEADS

 #34
20240269247
2024-08-15

Microbiome protection from oral antibiotics

 #35
20240245616
2024-07-25

METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER

 #36
20240226051
2024-07-11

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #37
20240226024
2024-07-11

SYNERGISTIC EFFECTS ON WEIGHT LOSS, IMPROVED QUALITY OF LIFE AND REDUCED GASTRO-INTESTINAL SIDE EFFECTS WITH A COMPOSITION OF ORLISTAT AND ACARBOSE

 #38
20240226023
2024-07-11

Compositions for Treatment of Attention Deficit Hyperactivity Disorder

 #39
20240226022
2024-07-11

TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION

 #40
20240180864
2024-06-06

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #41
20240180863
2024-06-06

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #42
20240180862
2024-06-06

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #43
20240180861
2024-06-06

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #44
20240180839
2024-06-06

DISINTEGRATING MONOLITHIC MODIFIED RELEASE TABLETS CONTAINING QUADRI-LAYER EXTENDED RELEASE GRANULES

 #45
20240173286
2024-05-30

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #46
20240165068
2024-05-23

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #47
20240148685
2024-05-09

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #48
20240139168
2024-05-02

ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE

 #49
20240130996
2024-04-25

PHARMACEUTICAL COMPOSITIONS AND PHARMACOKINETICS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE

 #50
20240108594
2024-04-04

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #51
20240091163
2024-03-21

SUSTAINED RELEASING PARTICLE AND METHOD OF PRODUCING SUSTAINED RELEASING PARTICLE

 #52
20240041803
2024-02-08

Lacosamide pharmaceutical composition and dosage form thereof

 #53
20240041782
2024-02-08

Oral Capsule Cannabinoid Formulations

 #54
20240009137
2024-01-11

ORAL THERAPEUTIC DELIVERY

 #55
20230390212
2023-12-07

TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION

 #56
20230381131
2023-11-30

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #57
20230381111
2023-11-30

METHOD AND SYSTEM FOR ADVANCED TECHNOLOGY PACKAGING AND DELIVERY OF ACTIVE CHEMICAL INGREDIENTS

 #58
20230320992
2023-10-12

SEQUENTIAL ADMINISTRATION OF PARTITIONED ABSORPTION ASPIRIN OR ACTIVE ASPIRIN DERIVATIVE AND COX-2 INHIBITOR

 #59
20230310332
2023-10-05

METHOD FOR MANUFACTURING A MULTI-LAYERED FILM STRUCTURE AND METHOD FOR MANUFACTURING MULTI-LAYERED MICROSTRUCURES

 #60
20230270830
2023-08-31

Microbiome protection from oral antibiotics

 #61
20230263810
2023-08-24

SYSTEMS, METHODS, AND COMPOSITIONS FOR INFECTIONS

 #62
20230263754
2023-08-24

SOLID DISPERSIONS AND PARTICLES AND METHODS FOR CONTROLLED-RELEASE OF LIPID-SOLUBLE OR DISPESIBLE ACTIVES

 #63
20230233472
2023-07-27

METHODS OF PREPARING MULTIPHASE STATIN AND OMEGA-3 FATTY ACID SOFT CAPSULE FORMULATIONS

 #64
20230210804
2023-07-06

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #65
20230190786
2023-06-22

Continuous release compositions made from hyaluronic acid, and therapeutic applications of same

 #66
20230183563
2023-06-15

MICROCAPSULE HAVING CORE-SHELL STRUCTURE, AND PRODUCTION METHOD FOR SAME

 #67
20230172893
2023-06-08

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #68
20230172892
2023-06-08

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #69
20230077636
2023-03-16

INTRAVENOUS FORMULATIONS OF RK-33

 #70
20230051463
2023-02-16

Methotrexate Dosage Form

 #71
20230014170
2023-01-19

INGESTIBLE MEDICAL DELIVERY DEVICES

 #72
20220362195
2022-11-17

DIMETHYL FUMARATE PARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF

 #73
20220323367
2022-10-13

ALKALINE PHOSPHATASE FORMULATIONS AND USES THEREOF

 #74
20220305004
2022-09-29

Methods of Using Low Dose Naltrexone to Treat Chronic Pain

 #75
20220296529
2022-09-22

PRE-FILLING SYSTEM TO ELIMINATE BUBBLES INSIDE CAPSULES HAVING A SOLID DOSAGE FORMS WITHIN SAID CAPSULES

 #76
20220280456
2022-09-08

Lacosamide pharmaceutical composition and dosage form thereof

 #77
20220241212
2022-08-04

Cariprazine release formulations

 #78
20220233456
2022-07-28

Methods and compositions particularly for treatment of attention deficit disorder

 #79
20220202762
2022-06-30

Benzonatate modified release solid tablets and capsules

 #80
20220183971
2022-06-16

POWDER FORMULATION FOR INTRANASAL ADMINISTRATION, AND MANUFACTURING METHOD THEREOF

 #81
20220175695
2022-06-09

FORTIFICANT COMPOSITION

 #82
20220162160
2022-05-26

Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto

 #83
20220110878
2022-04-14

Compositions for treatment of attention deficit hyperactivity disorder

 #84
20220110877
2022-04-14

Compositions for Treatment of Attention Deficit Hyperactivity Disorder

 #85
20220105064
2022-04-07

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #86
20220105047
2022-04-07

MICROCAPSULE COMPOSITION USING ALGINATE GEL, AND METHOD FOR PRODUCING SAME

 #87
20220088268
2022-03-24

Particulate coated hydrogel microparticles

 #88
20220062188
2022-03-03

All-in-one fixed-dose combination for treating infection

 #89
20220054452
2022-02-24

Duloxetine sprinkles

 #90
20220047558
2022-02-17

Methods and compositions for treating hyperhidrosis

 #91
20220040127
2022-02-10

Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

 #92
20220023247
2022-01-27

Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative

 #93
20220016066
2022-01-20

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #94
20220016041
2022-01-20

Once Daily Formulations Of Tetracyclines

 #95
20210379013
2021-12-09

ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY

 #96
20210369629
2021-12-02

PHARMACEUTICAL BEAD FORMULATIONS COMPRISING DIMETHYL FUMARATE

 #97
20210361608
2021-11-25

Stabilized microcapsules, method of their preparation and uses thereof

 #98
20210361586
2021-11-25

Stabilized microcapsules, method of their preparation and uses thereof

 #99
20210361583
2021-11-25

STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF

 #100
20210322408
2021-10-21

Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate

 #101
20210315870
2021-10-14

COMBINATORIAL TARGETED THERAPY METHODS

 #102
20210290557
2021-09-23

MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION, IMMEDIATE RELEASE PELLETS, SUSTAINED RELEASE PELLETS, ENTERIC RELEASE PELLETS AND USE THEREOF

 #103
20210283076
2021-09-16

Lacosamide pharmaceutical composition and dosage form thereof

 #104
20210267928
2021-09-02

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

 #105
20210251910
2021-08-19

FUMARIC ACID COMPOSITIONS WITH INCREASED BIOAVAILABILITY AND REDUCED SIDE EFFECTS

 #106
20210244723
2021-08-12

Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2

 #107
20210244719
2021-08-12

Oral pharmaceutical compositions of dabigatran etexilate

 #108
20210220452
2021-07-22

Microbiome protection from oral antibiotics

 #109
20210220318
2021-07-22

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #110
20210196572
2021-07-01

PRODUCING EROSION-CONTROLLED RELEASE DEVICES

 #111
20210186916
2021-06-24

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #112
20210177768
2021-06-17

Cariprazine release formulations

 #113
20210145756
2021-05-20

PHARMACEUTICAL COMPOSITIONS

 #114
20210128549
2021-05-06

OXYCODONE AND METHYLNALTREXONE MULTIPARTICULATES AND SUSPENSIONS CONTAINING THEM

 #115
20210106560
2021-04-15

Duloxetine sprinkles

 #116
20210100750
2021-04-08

Compositions for treatment of attention deficit hyperactivity disorder

 #117
20210077416
2021-03-18

Compositions for treatment of attention deficit hyperactivity disorder

 #118
20210030669
2021-02-04

Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix

 #119
20210008212
2021-01-14

Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions

 #120
20200390742
2020-12-17

CLINICALLY EFFICACIOUS ANTI-METHANOGENIC COMPOSITIONS AND USES

 #121
20200390713
2020-12-17

Celecoxib and amlodipine formulation and method of making the same

 #122
20200390709
2020-12-17

PROCEDURE FOR PREPARING ENTERIC-COATED PELLETS CONTAINING A PROTON PUMP INHIBITOR AND MULTI-PARTICLE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

 #123
20200330654
2020-10-22

Degradable removable implant for the sustained release of an active compound

 #124
20200306379
2020-10-01

Injectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

 #125
20200306200
2020-10-01

METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER

 #126
20200306196
2020-10-01

Ingestible medical delivery devices

 #127
20200297650
2020-09-24

TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION

 #128
20200289498
2020-09-17

Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

 #129
20200276168
2020-09-03

Sustained Release Pharmaceutical Compositions and Methods of Use

 #130
20200268677
2020-08-27

Minimizing aeration of suspensions during in-line mixing

 #131
20200255372
2020-08-13

SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO

 #132
20200253952
2020-08-13

Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

 #133
20200246470
2020-08-06

Microparticles containing finasteride and preparation method thereof

 #134
20200230083
2020-07-23

Composition comprising suplatast tosilate

 #135
20200197347
2020-06-25

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #136
20200197317
2020-06-25

Compositions for treatment of attention deficit hyperactivity disorder

 #137
20200197316
2020-06-25

Compositions for treatment of attention deficit hyperactivity disorder

 #138
20200188360
2020-06-18

Methods and compositions for treating hyperhidrosis

 #139
20200188352
2020-06-18

ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY

 #140
20200179395
2020-06-11

PHARMACEUTICAL COMPOSITIONS

 #141
20200163926
2020-05-28

Benzonatate modified release solid tablets and capsules

 #142
20200163896
2020-05-28

FLOATABLE PHARMACEUTICAL MICROCAPSULE COMPOSITION

 #143
20200138725
2020-05-07

Anti-inflammatory pharmaceutical compositions and methods of administration

 #144
20200078334
2020-03-12

Duloxetine sprinkles

 #145
20200069597
2020-03-05

Timed, pulsatile release systems

 #146
20200061191
2020-02-27

Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions

 #147
20200054627
2020-02-20

Treating pain in patients with hepatic impairment

 #148
20200030242
2020-01-30

ORAL DOSAGE FORM WITH DRYING AGENT FOR DELIVERY OF ACTIVE AGENT

 #149
20200025747
2020-01-23

Stimuli responsive microsphere composites

 #150
20200000791
2020-01-02

ORAL PHARMACEUTICAL DOSAGE FORMS

 #151
20190388416
2019-12-26

Concentrated, inhalable ciprofloxacin formulation

 #152
20190388340
2019-12-26

Oral pH independent dosage formulation for treating neurodegenerative disorders

 #153
20190380969
2019-12-19

Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride

 #154
20190358253
2019-11-28

COMPOSITION COMPRISING IMMEDIATE RELEASE AND EXTENDED RELEASE CAPECITABINE

 #155
20190350897
2019-11-21

ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY

 #156
20190350868
2019-11-21

Tamper resistant oral opioid agonist formulations

 #157
20190343787
2019-11-14

Controlled release pharmaceutical compositions comprising a fumaric acid ester

 #158
20190343775
2019-11-14

Modified resveratrol composition and use thereof

 #159
20190336451
2019-11-07

Rifabutin-based compositions and methods for treating infection

 #160
20190314369
2019-10-17

Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate

 #161
20190314356
2019-10-17

Effective dosing of a child for the treatment of ADHD with methylphenidate

 #162
20190314290
2019-10-17

Methods and compositions particularly for treatment of attention deficit disorder

 #163
20190307727
2019-10-10

Methods and compositions for treating hyperhidrosis

 #164
20190307702
2019-10-10

Multiparticulates of spray-coated drug and polymer on a meltable core

 #165
20190298665
2019-10-03

Delayed release cysteamine bead formulation, and methods of making and using same

 #166
20190298656
2019-10-03

Particulate coated hydrogel microparticles

 #167
20190282532
2019-09-19

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #168
20190282508
2019-09-19

EXTENDED RELEASE DRUG FORMULATION WITH OVERDOSE PROTECTION AND ABUSE DETERRENCE

 #169
20190282507
2019-09-19

Celecoxib and amlodipine formulation and method of making the same

 #170
20190274990
2019-09-12

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #171
20190274966
2019-09-12

Casein-based silica dual drug-loading composite microcapsule and preparation method therefor

 #172
20190269764
2019-09-05

POWDER FORMULATION

 #173
20190269641
2019-09-05

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #174
20190269640
2019-09-05

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #175
20190262273
2019-08-29

Methods and compositions particularly for treatment of attention deficit disorder

 #176
20190254982
2019-08-22

Methods and compositions particularly for treatment of attention deficit disorder

 #177
20190254981
2019-08-22

Methods and compositions particularly for treatment of attention deficit disorder

 #178
20190224131
2019-07-25

DELAYED-RELEASE FORMULATIONS, METHODS OF MAKING AND USE THEREOF

 #179
20190216931
2019-07-18

INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

 #180
20190216741
2019-07-18

Formulations of cysteamine and cysteamine derivatives

 #181
20190201368
2019-07-04

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #182
20190201355
2019-07-04

Method for relieving sinus congestion

 #183
20190183836
2019-06-20

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #184
20190183817
2019-06-20

EXTENDED RELEASE SUSPENSIONS OF MIXTURES OF DEXTRO- AND LEVO-AMPHETAMINES

 #185
20190183809
2019-06-20

Methods and compositions particularly for treatment of attention deficit disorder

 #186
20190183808
2019-06-20

Methods and compositions particularly for treatment of attention deficit disorder

 #187
20190175512
2019-06-13

Methods for treating helicobacter pylori infection

 #188
20190167663
2019-06-06

Abuse resistant pharmaceutical compositions

 #189
20190167597
2019-06-06

Tamper resistant pharmaceutical formulations

 #190
20190125824
2019-05-02

Powder formulation

 #191
20190125689
2019-05-02

Compositions for treatment of attention deficit hyperactivity disorder

 #192
20190125683
2019-05-02

Once Daily Formulations Of Tetracyclines

 #193
20190117793
2019-04-25

MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES

 #194
20190117734
2019-04-25

System and Method for Multiphasic Release of Growth Factors

 #195
20190117674
2019-04-25

Method of treatment using nanoparticulate ganaxolone formulations

 #196
20190117673
2019-04-25

GANAXOLONE FORMULATION AND USE THEREOF

 #197
20190117613
2019-04-25

Controlled release pharmaceutical compositions comprising a fumaric acid ester

 #198
20190117599
2019-04-25

Solid oral formulation of fenretinide

 #199
20190099380
2019-04-04

Composition and method for pretreating cancer

 #200
20190091193
2019-03-28

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #201
20190091192
2019-03-28

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #202
20190091191
2019-03-28

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #203
20190083484
2019-03-21

Formulations And Pharmacokinetics Of Deuterated Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2

 #204
20190083434
2019-03-21

Compositions and methods of using modified release solabegron for lower urinary tract symptoms

 #205
20190083433
2019-03-21

COMPOSITIONS AND METHODS OF USING MODIFIED RELEASE SOLABEGRON FOR LOWER URINARY TRACT SYMPTOMS

 #206
20190083413
2019-03-21

Anti-inflammatory pharmaceutical compositions and methods of administration

 #207
20190083399
2019-03-21

DRUG DELIVERY COMPOSITION

 #208
20190076370
2019-03-14

Methods and compositions particularly for treatment of attention deficit disorder

 #209
20190076369
2019-03-14

Timed, pulsatile release systems

 #210
20190070143
2019-03-07

Dimethyl fumarate particles and pharmaceutical compositions thereof

 #211
20190070132
2019-03-07

Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

 #212
20190054031
2019-02-21

OVERDOSE PROTECTION AND ABUSE DETERRENT IMMEDIATE RELEASE DRUG FORMULATION

 #213
20190046460
2019-02-14

Methods and compositions particularly for treatment of attention deficit disorder

 #214
20190046456
2019-02-14

Pharmaceutical bead formulations comprising dimethyl fumarate

 #215
20190029964
2019-01-31

Sumatriptan promethazine pharmaceutical compositions

 #216
20190022015
2019-01-24

Ingestible medical delivery devices

 #217
20190008777
2019-01-10

Celecoxib and amlodipine formulation and method of making the same

 #218
20190000769
2019-01-03

Methods and compositions particularly for treatment of attention deficit disorder

 #219
20180344728
2018-12-06

PHARMACEUTICAL COMPOSITIONS

 #220
20180338966
2018-11-29

Treating pain in patients with hepatic impairment

 #221
20180325892
2018-11-15

PHARMACEUTICAL COMPOSITIONS

 #222
20180325855
2018-11-15

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #223
20180311217
2018-11-01

METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS

 #224
20180311170
2018-11-01

Pharmaceutical composition containing clomipramine and preparation method therefor

 #225
20180296594
2018-10-18

SOLID ORAL DOSAGE FORM FOR BREAST SYMPTOMS

 #226
20180263957
2018-09-20

DULOXETINE SPRINKLES

 #227
20180263947
2018-09-20

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #228
20180263932
2018-09-20

Method for relieving sinus congestion

 #229
20180256492
2018-09-13

Devices, formulations, and methods for delivery of multiple beneficial agents

 #230
20180250271
2018-09-06

Pharmaceutical antiretroviral composition

 #231
20180243218
2018-08-30

Pharmaceutical formulations

 #232
20180235895
2018-08-23

Methods and compositions particularly for treatment of attention deficit disorder

 #233
20180221511
2018-08-09

Multi-encapsulated formulations made with oxidized cellulose

 #234
20180221314
2018-08-09

ORAL LIQUID COMPOSITIONS OF GUANFACINE

 #235
20180221290
2018-08-09

EXTENDED RELEASE SUSPENSION COMPOSITIONS

 #236
20180214435
2018-08-02

Oral pharmaceutical dosage forms

 #237
20180200221
2018-07-19

BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES

 #238
20180193277
2018-07-12

GAMMA-HYDROXYBUTYRIC ACID GRANULES

 #239
20180177731
2018-06-28

Composite preparation of mosapride and rabeprazole

 #240
20180169082
2018-06-21

DONEPEZIL COMPOSITIONS AND METHODS OF TREATING ALZHEIMERS DISEASE

 #241
20180169027
2018-06-21

Treating infection by a platelet-targeting microbe using nanoparticles

 #242
20180169026
2018-06-21

Rumen protected glucose and method of preparation

 #243
20180161306
2018-06-14

Duloxetine sprinkles

 #244
20180153818
2018-06-07

PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS

 #245
20180153806
2018-06-07

Combination liposomal pharmaceutical formulations

 #246
20180147152
2018-05-31

RAPID DISSOLVE TABLET COMPOSITIONS FOR VAGINAL ADMINISTRATION

 #247
20180125978
2018-05-10

Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions

 #248
20180116961
2018-05-03

Stimulant abuse-deterrent compositions

 #249
20180098957
2018-04-12

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #250
20180078505
2018-03-22

Procedure for preparing enteric-coated pellets containing a proton pump inhibitor and multi-particle pharmaceutical compositions containing them

 #251
20180064662
2018-03-08

NOVEL COMPOSITIONS AND USES OF METFORMIN AGENTS

 #252
20180049974
2018-02-22

ABUSE-RESISTANT FORMULATIONS

 #253
20180042989
2018-02-15

IMMUNOMODULATORY COMPOSITIONS

 #254
20180042859
2018-02-15

Tamper resistant oral opioid agonist formulations

 #255
20180042854
2018-02-15

Methods of treating attention deficit hyperactivity disorder

 #256
20180028528
2018-02-01

ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

 #257
20180028483
2018-02-01

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

 #258
20180021284
2018-01-25

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

 #259
20180015080
2018-01-18

COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS

 #260
20180008544
2018-01-11

Controlled release formulations

 #261
20180000752
2018-01-04

Pulsed release phenylephrine dosage forms

 #262
20170348263
2017-12-07

COMPOSITIONS AND METHODS OF USING MODIFIED RELEASE SOLABEGRON FOR LOWER URINARY TRACT SYMPTOMS

 #263
20170340707
2017-11-30

System and Method for Multiphasic Release of Growth Factors

 #264
20170319576
2017-11-09

Abuse resistant pharmaceutical compositions

 #265
20170319514
2017-11-09

DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME

 #266
20170319513
2017-11-09

DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME

 #267
20170319512
2017-11-09

DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME

 #268
20170305843
2017-10-26

Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto

 #269
20170290772
2017-10-12

STABLE MICELLE AND/OR LIPOSOME COMPOSITIONS AND USES THEREOF

 #270
20170290768
2017-10-12

Compositions and methods for selective GI tract delivery

 #271
20170273975
2017-09-28

Pharmaceutical composition having abuse deterrent properties

 #272
20170266259
2017-09-21

System and Method for Multiphasic Release of Growth Factors

 #273
20170266121
2017-09-21

Sustained-release formulations of topiramate

 #274
20170252330
2017-09-07

Oral pharmaceutical dosage forms

 #275
20170252302
2017-09-07

Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates

 #276
20170216215
2017-08-03

Tamper resistant pharmaceutical formulations

 #277
20170209381
2017-07-27

Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

 #278
20170202778
2017-07-20

Methods and compositions for treating hyperhidrosis

 #279
20170189341
2017-07-06

Pharmaceutical compositions for the treatment of

#280
20170182135
2017-06-29

DRY POWDER FIBRIN SEALANT

 #281
20170182031
2017-06-29

REDUCING DRUG LIKING IN A SUBJECT

 #282
20170135959
2017-05-18

Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same

 #283
20170119685
2017-05-04

Tamper resistant oral opioid agonist formulations

 #284
20170112774
2017-04-27

Timed, pulsatile release systems

 #285
20170100480
2017-04-13

Controlled release formulations of levodopa and uses thereof

 #286
20170087248
2017-03-30

Biodegradable microsphere-hydrogel ocular drug delivery system

 #287
20170079937
2017-03-23

Compositions for treatment of attention deficit hyperactivity disorder

 #288
20170079921
2017-03-23

Methods of preparing oral controlled release formulations

 #289
20170071926
2017-03-16

Methods of treating attention deficit hyperactivity disorder

 #290
20170071864
2017-03-16

Compositions for treatment of attention deficit hyperactivity disorder

 #291
20170065522
2017-03-09

Pharmaceutical formulations

 #292
20170035753
2017-02-09

Concentrated, inhalable ciprofloxacin formulation

 #293
20170035745
2017-02-09

Pharmaceutical combinations of dabigatran and proton pump inhibitors

 #294
20170027870
2017-02-02

Extended release pharmaceutical compositions

 #295
20170000783
2017-01-05

Multiparticulate Modified Release Composition

 #296
20160375048
2016-12-29

Sustained-release formulations of topiramate

 #297
20160375015
2016-12-29

Pharmaceutical compositions

 #298
20160367550
2016-12-22

Naloxone single agent and multilayer tablets

 #299
20160346274
2016-12-01

Abuse-resistant drug formulations with built-in overdose protection

 #300
20160346235
2016-12-01

Oral liquid compositions of guanfacine